Archives: Projects/Publication

Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure–induced transient ischemic injury

Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure–induced transient ischemic injury

Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure–induced transient ischemic injury

Madeira MH, Boia R, Elvas F, Martins T, Cunha RA, Ambrósio AF, Santiago AR

Translational Research 2016; 169:112–128

2016

Protective Effect of a GLP-1 Analog on Ischemia- Reperfusion Induced Blood–Retinal Barrier Breakdown and Inflammation

Protective Effect of a GLP-1 Analog on Ischemia- Reperfusion Induced Blood–Retinal Barrier Breakdown and Inflammation

Protective Effect of a GLP-1 Analog on Ischemia- Reperfusion Induced Blood–Retinal Barrier Breakdown and Inflammation

A Gonçalves, CM Lin, A. Muthusamy, C Fontes-Ribeiro, AF Ambrósio, SF Abcouwer, R Fernandes and DA Antonetti

Invest Ophthalmol Vis Sci. 2016;57:2584–2592. DOI:10.1167/iovs.15-19006

2016

Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma

Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma

Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma

MH Madeira, A Ortin-Martinez, F Nadal-Nícolas, AF Ambrósio, M Vidal-Sanz, M Agudo-Barriuso and AR Santiago

Scientific Reports. 6:27532. DOI: 10.1038/srep27532

2016

Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial

Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial

Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial

Trento M, Durando O, Lavecchia S, Charrier L, Cavallo F, Costa MA, Hernández C, Simó R, Porta M, for the EUROCONDOR trial investigators.

Endocrine DOI 10.1007/s12020-016-1097-0

2016

Correlation between Retinal Vessel Calibre and Neurodegeneration in Patients with Type 2 Diabetes Mellitus in the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)

Correlation between Retinal Vessel Calibre and Neurodegeneration in Patients with Type 2 Diabetes Mellitus in the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)

Correlation between Retinal Vessel Calibre and Neurodegeneration in Patients with Type 2 Diabetes Mellitus in the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)

Frydkjaer-Olsen U, Hansen RS, Simó R, Cunha-Vaz J, Peto T, Grauslund J on behalf of the EUROCONDOR

Ophthalmic Res. 2016;56:10-16. DOI: 10.1159/000444396

2016